Sample size determination for proving equivalence based on the ratio of two means for normally distributed data
- PMID: 9990695
- DOI: 10.1002/(sici)1097-0258(19990115)18:1<93::aid-sim992>3.0.co;2-8
Sample size determination for proving equivalence based on the ratio of two means for normally distributed data
Abstract
Equivalence trials aim to demonstrate that two treatments do not differ by more than a prespecified clinically irrelevant amount. We consider the problem when equivalence is defined in terms of the ratio of population means and the original (untransformed) data are normally distributed. Application of the intersection-union principle to the test proposed by Sasabuchi results in a two one-sided tests procedure of size alpha. We give the associated 100 (1-2 alpha) per cent confidence interval and derive the exact methods for calculation of power and sample sizes for the parallel group design and the two-period cross-over. We present tables and figures of required sample sizes and achieved power.
Similar articles
-
Sample size determination for a three-arm equivalence trial of normally distributed responses.J Biopharm Stat. 2014;24(6):1190-202. doi: 10.1080/10543406.2014.948552. J Biopharm Stat. 2014. PMID: 25098678
-
Exact sample-size determination in testing non-inferiority under a simple crossover trial.Pharm Stat. 2012 Mar-Apr;11(2):129-34. doi: 10.1002/pst.506. Epub 2012 Jan 10. Pharm Stat. 2012. PMID: 22232060
-
Asthma management: the challenge of equivalence.Int J Clin Pharmacol Ther. 1998 Mar;36(3):117-25. Int J Clin Pharmacol Ther. 1998. PMID: 9562226
-
Sample size calculations for risk equivalence testing in pharmacoepidemiology.J Clin Epidemiol. 2000 Dec;53(12):1268-74. doi: 10.1016/s0895-4356(00)00252-3. J Clin Epidemiol. 2000. PMID: 11146274 Review.
-
Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children.Pediatr Infect Dis J. 2002 Aug;21(8):753-8. doi: 10.1097/00006454-200208000-00011. Pediatr Infect Dis J. 2002. PMID: 12192164
Cited by
-
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):147-60. doi: 10.1007/s10928-011-9235-z. Epub 2012 Jan 21. J Pharmacokinet Pharmacodyn. 2012. PMID: 22270321 Clinical Trial.
-
Fear or favour? Statistics in pathology.J Clin Pathol. 2000 Jan;53(1):16-8. doi: 10.1136/jcp.53.1.16. J Clin Pathol. 2000. PMID: 10767848 Free PMC article. Review. No abstract available.
-
Equivalence concepts in clinical trials.Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):38-40. doi: 10.1007/BF03190056. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11032089
-
A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol.Stem Cells Int. 2018 Feb 22;2018:6025918. doi: 10.1155/2018/6025918. eCollection 2018. Stem Cells Int. 2018. PMID: 29535772 Free PMC article.
-
Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.Br J Clin Pharmacol. 2010 Oct;70(4):523-36. doi: 10.1111/j.1365-2125.2010.03731.x. Br J Clin Pharmacol. 2010. PMID: 20840444 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical